$59.18
-0.74-1.23%
Dern. MÀJ: Oct 14, 1:26 PM
$59.50
-0.42-0.7%
PTC Therapeutics (PTCT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
fiscal year (2026) a publié ses dernières prévisions le $1.18B - $1.28B pour PTC Therapeutics {{epsDirection}}. La société a prévu un chiffre d'affaires compris entre {{epsPriorRange}} et {{revenueDirection}} pour la période.
Par rapport aux prévisions précédentes, {{newestDate}} {{directionSummary}} ses prévisions de chiffre d'affaires ont été revues à la baisse, passant d'une fourchette précédente de undefined à undefined.
undefined a publié undefined mises à jour de ses recommandations entre undefined et undefined. undefined
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.31 | $-0.41 | $-0.33 | $-1.14 |
| Actual | $0.92 | $-0.03 | $-1.67 | $0.20 |
| Surprise | +196.8% | +92.7% | -406.1% | +117.5% |
| Revenue | ||||
| Estimate | $292.7M | $227.5M | $295.4M | $175.5M |
| Actual | $360.5M | $272.6M | $164.7M | $211.0M |
| Surprise | +23.2% | +19.8% | -44.3% | +20.2% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.27 | $0.15 | $0.07 | $0.16 |
| Revenue | ||||
| Consensus | $304.4M | $321.5M | — | — |
| Trimestre Fiscal | Date de Déclaration | BPA Réel | BPA Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $0.92 | $0.31 | 196.8 % |
| Q1 | May 7, 2026 | $-0.03 | $-0.41 | 92.7 % |
| Q4 | Feb 19, 2026 | $-1.67 | $-0.33 | -406.1 % |
| Q3 | Nov 4, 2025 | $0.20 | $-1.14 | 117.5 % |
| Trimestre Fiscal | Date de Déclaration | Revenu Réel | Revenu Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $360.52M | $292.70M | 23.2 % |
| Q1 | May 7, 2026 | $272.55M | $227.52M | 19.8 % |
| Q4 | Feb 19, 2026 | $164.68M | $295.44M | -44.3 % |
| Q3 | Nov 4, 2025 | $211.01M | $175.55M | 20.2 % |